Major Depressive Disorder In The Elderly

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

364 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-06-30

Study Completion Date

2005-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a placebo-controlled study evaluating the effectiveness of medication in elderly subjects with Major Depressive Disorder (MDD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan

NCT00330616

Major Depressive Disorder (MDD)

COMPLETED PHASE2

Study Of 323U66 SR In Major Depressive Disorder

NCT00135512

Depressive Disorder

COMPLETED PHASE2

A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression

NCT03623711

Major Depressive Disorder Depression, Unipolar

UNKNOWN EARLY_PHASE1

Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression

NCT03833063

Major Depressive Disorder Major Depressive Episode Treatment Resistant Depression

WITHDRAWN PHASE1

Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

NCT02960763

Treatment Resistant Depression Major Depressive Disorder Treatment-Refractory Depression +2 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Major

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bupropion XL

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary diagnosis of Major Depressive Disorder with DSM-IV criteria for their current episode for at least 8 weeks.

Exclusion Criteria

* Patient has current or past history of seizure disorder or brain injury.
* Patient has a diagnosis of anorexia or bulimia within the past 12 months.
* Patient has a past or current DMS-IV diagnosis of schizophrenia or any other psychotic disorder(s).
* Patient has had a myocardial infarction within 1 year or a history of uncontrolled hypertension or unstable heart disease with 6 months.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No